Erlotinib and Temozolomide With Radiation Therapy in Treating Patients With Glioblastoma Multiforme or Other Brain Tumors
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This pilot phase II trial is studying the side effects and best dose of erlotinib when given
with temozolomide and radiation therapy and to see how well they work in treating patients
with glioblastoma multiforme or other brain tumors. Radiation therapy uses high-energy x-rays
to damage tumor cells. Erlotinib may interfere with the growth of tumor cells, slow the
growth of the tumor, and make the tumor cells more sensitive to radiation therapy. Drugs used
in chemotherapy, such as temozolomide, work in different ways to stop tumor cells from
dividing so they stop growing or die. Combining erlotinib and temozolomide with radiation
therapy may kill more tumor cells.